Omeros stock craters as FDA cites deficiencies in application for HSCT-TMA drug
Omeros’ stock price fell by more than 40% in early trading Friday as the company disclosed that the FDA has found deficiencies in its application …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
